Compound brief
Evidence brief. Not treatment advice or a safety clearance. Last evidence update: September 2026.
Discussed as a synaptogenesis research compound through HGF/c-Met. c-Met is also an oncogene pathway. No marker on this sheet scores that pathway, so no cognitive benefit is stored.
Forum "genius peptide" language is Grade F. Absence of a marker is not a safety finding.
The protocol library files Dihexa under HGF/c-Met potentiation and early animal or cell synaptogenesis work.
c-Met is an oncogene pathway as well as a synapse story. No marker is stored, so the checker does not invent a benefit or a harm score from the name.
Forum themes are unverified. They do not outrank a study, and they are not a dose.
Genius-peptide claim · unverified
Forums call Dihexa a genius peptide and stack it with Semax. The protocol library says human cognition trials are absent and the c-Met story is a caution. Those posts are not a result.
From the Catalyst protocol research library. Community schedules there are Grade F and are not a dose.